Top Page
BCAL Diagnostics Limited
(Sydney:BDX)
BCAL Diagnostics Limited (BDX) vs. iShares MSCI Australia ETF (EWA)
BCAL Diagnostics Limited Business Overview & Revenue Model
BCAL Diagnostics Limited Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.65M | 21.64K | 3.10M | 2.79M | 718.67K | 275.25K |
| Gross Profit | 2.65M | 21.64K | 3.10M | 2.79M | 698.06K | 275.25K |
| EBITDA | -6.31M | -6.19M | -5.67M | -7.72M | -4.06M | -1.80M |
| Net Income | -7.24M | -7.24M | -6.40M | -5.06M | -3.39M | -1.52M |
Balance Sheet | ||||||
| Total Assets | 9.91M | 9.91M | 12.27M | 8.37M | 10.59M | 4.13M |
| Cash, Cash Equivalents and Short-Term Investments | 4.52M | 4.52M | 6.47M | 3.17M | 9.57M | 3.41M |
| Total Debt | 2.38M | 2.38M | 1.52M | 1.06M | 0.00 | 0.00 |
| Total Liabilities | 3.69M | 3.69M | 3.68M | 3.16M | 950.42K | 525.60K |
| Stockholders Equity | 6.22M | 6.22M | 8.59M | 5.21M | 9.64M | 3.61M |
Cash Flow | ||||||
| Free Cash Flow | -6.92M | -6.92M | -5.67M | -6.41M | -7.25M | -1.21M |
| Operating Cash Flow | -6.14M | -6.14M | -4.52M | -6.05M | -3.22M | -1.21M |
| Investing Cash Flow | -787.67K | -787.67K | -1.15M | 3.64M | -4.03M | -3.85K |
| Financing Cash Flow | 4.97M | 4.97M | 8.97M | 13.24K | 9.41M | 4.20M |
BCAL Diagnostics Limited Technical Analysis
BCAL Diagnostics Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | AU$34.21M | -4.70 | -97.79% | ― | ― | 23.85% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$141.69M | ― | -111.23% | ― | 12.96% | 40.81% | |
44 Neutral | AU$27.68M | -6.59 | -501.54% | ― | ― | 56.42% | |
39 Underperform | AU$10.77M | -2.11 | ― | ― | -47.02% | 94.37% | |
38 Underperform | AU$49.96M | -5.78 | -37.78% | ― | 2.33% | 12.50% |
BCAL Diagnostics Limited Corporate Events
BCAL Diagnostics Limited has announced a proposed issue of 10,000,000 convertible debt securities. This move is part of a placement or other type of issue, with the proposed issue date set for November 27, 2025. The announcement indicates a strategic financial maneuver aimed at raising capital, which could impact the company’s market positioning and stakeholder interests.
BCAL Diagnostics Limited has announced the establishment of a $10 million Convertible Note facility to bolster its working capital and support its commercialization strategy. With firm commitments for $5 million already secured, this facility strengthens BCAL’s capital position, enabling the company to progress its commercial and technical milestones, particularly in delivering innovative cancer detection solutions. The facility offers favorable terms, including a 10% annual interest rate and conversion options into ordinary shares, subject to shareholder approval.
BCAL Diagnostics Limited has announced the establishment of a $10 million Convertible Note facility to support its working capital and commercialization strategy. With firm commitments for $5 million, the facility is expected to bolster BCAL’s capital position, enabling the company to progress its commercial and clinical milestones, and expand its pipeline of cancer detection tests. This move is seen as pivotal for BCAL’s growth, providing financial flexibility to advance its mission of delivering innovative cancer detection solutions.
BCAL Diagnostics Limited has entered into a strategic partnership with ClearNote Health, granting BCAL exclusive distribution rights for ClearNote’s Avantect Pancreatic and Avantect Ovarian tests in Australia and New Zealand. This agreement, initially set for two years with potential extensions, positions BCAL to enhance its market presence in the early detection cancer test industry, potentially impacting its operations and stakeholder interests positively.
BCAL Diagnostics Limited announced it will host an investor webinar on 24 September 2025, featuring presentations from its Executive Chair and CEO. This event is part of BCAL’s ongoing efforts to engage with investors and stakeholders, potentially impacting its market positioning and stakeholder relations.
BCAL Diagnostics Limited has entered an exclusive agreement with ClearNote Health to distribute advanced blood tests for pancreatic and ovarian cancer in Australia and New Zealand. This strategic partnership enhances BCAL’s position in the cancer detection market by expanding its portfolio beyond breast cancer tests, potentially saving lives through early detection of high-mortality cancers.
BCAL Diagnostics Limited has released its corporate governance statement for the financial year ending June 30, 2025, which is available on their website. The statement outlines the company’s adherence to the ASX Corporate Governance Council’s principles and recommendations, highlighting its commitment to transparency and accountability in its operations.
BCAL Diagnostics Limited has launched BREASTESTplus™, a non-invasive diagnostic test designed to enhance breast cancer detection in women with dense breast tissue. This launch marks a significant milestone for the company, aligning with recent policy changes in breast screening and generating initial commercial sales. The product is now available in multiple clinics and supported by a strategic partnership with Cancer Care Associates and the Sydney Breast Clinic, expanding its market reach and integration into specialist workflows.
BCAL Diagnostics Limited has launched its BREASTEST plus™ in New South Wales, targeting breast cancer clinics in Sydney and Melbourne. The initial commercial rollout has been successful, with 107 tests sold and partnerships established with eight clinics and 33 breast specialists. The company has expanded its market access strategy to include general practitioners, enhancing doctor engagement and patient referrals. A strategic partnership with Cancer Care Associates has further increased access to the test. The recent policy update by BreastScreen Australia on breast density reporting supports the clinical uptake of BREASTEST plus™, highlighting its importance in early cancer detection where traditional mammography is less effective.